BRPI0607648A2 - composição dermatológica, sal, bem como o uso destas composições - Google Patents

composição dermatológica, sal, bem como o uso destas composições

Info

Publication number
BRPI0607648A2
BRPI0607648A2 BRPI0607648-3A BRPI0607648A BRPI0607648A2 BR PI0607648 A2 BRPI0607648 A2 BR PI0607648A2 BR PI0607648 A BRPI0607648 A BR PI0607648A BR PI0607648 A2 BRPI0607648 A2 BR PI0607648A2
Authority
BR
Brazil
Prior art keywords
compositions
dermatological
salt
well
dermatological composition
Prior art date
Application number
BRPI0607648-3A
Other languages
English (en)
Inventor
Morten Sloth Weider
Original Assignee
Astion Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astion Pharma As filed Critical Astion Pharma As
Publication of BRPI0607648A2 publication Critical patent/BRPI0607648A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçãO DERMATOLóGICA, SAL, BEM COMO O USO DESTAS COMPOSIçõES. A presente invenção refere-se a composições dermatológicas de Oxaprozina ou a um composto intimamente relacionado adaptado para o tratamento de uma doença dermatológica, onde pelo menos duas das enzimas selecionadas a partir de proteína tirosina cinase Syk, proteína tirosina cinase ZAP-70 e fosfodiesterase IV desempenham um papel na mediação da doença dermatológica. A invenção também abrange composições dermatológicas para o tratamento de prurido.
BRPI0607648-3A 2005-03-30 2006-03-30 composição dermatológica, sal, bem como o uso destas composições BRPI0607648A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200500437 2005-03-30
DKPA200500438 2005-03-30
US69477405P 2005-06-27 2005-06-27
DKPA200500948 2005-06-27
DKPA200500949 2005-06-27
US69504005P 2005-06-28 2005-06-28
PCT/DK2006/000181 WO2006102900A1 (en) 2005-03-30 2006-03-30 Dermatological compositions and salts for the treatment of dermatological diseases

Publications (1)

Publication Number Publication Date
BRPI0607648A2 true BRPI0607648A2 (pt) 2009-09-22

Family

ID=36215671

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0607648-3A BRPI0607648A2 (pt) 2005-03-30 2006-03-30 composição dermatológica, sal, bem como o uso destas composições
BRPI0609535-6A BRPI0609535A2 (pt) 2005-03-30 2006-03-30 uso de oxaprozina na preparação de um medicamento para o tratamento de eczemas
BRPI0609653-0A BRPI0609653A2 (pt) 2005-03-30 2006-03-30 tratamento ou prevenção de prurido

Family Applications After (2)

Application Number Title Priority Date Filing Date
BRPI0609535-6A BRPI0609535A2 (pt) 2005-03-30 2006-03-30 uso de oxaprozina na preparação de um medicamento para o tratamento de eczemas
BRPI0609653-0A BRPI0609653A2 (pt) 2005-03-30 2006-03-30 tratamento ou prevenção de prurido

Country Status (12)

Country Link
EP (3) EP1707201A1 (pt)
JP (3) JP2008534526A (pt)
KR (3) KR20080011280A (pt)
AU (3) AU2006228869A1 (pt)
BR (3) BRPI0607648A2 (pt)
CA (3) CA2603300A1 (pt)
EA (3) EA200702026A1 (pt)
EC (3) ECSP077845A (pt)
IL (3) IL186021A0 (pt)
MX (3) MX2007012051A (pt)
NO (3) NO20075199L (pt)
WO (3) WO2006102898A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821537D0 (en) * 2008-11-25 2008-12-31 Union Life Sciences Ltd Therapeutic target
WO2017045081A1 (en) * 2015-09-18 2017-03-23 Delivra Inc. Transdermal formulations for delivery of propionic and acetic acid nsaids, and their use in the treatment of nsaid-responsive diseases and conditions
WO2018031529A1 (en) * 2016-08-08 2018-02-15 Avedro, Inc. Systems and methods for cross-linking treatments of an eye
CN110035749B (zh) 2016-10-25 2022-11-15 蒂库尔有限公司 Fabp4作为皮肤病中的治疗靶
CA3083786A1 (en) * 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations of pde-4 inhibitor and their use in treating skin conditions
RU2685436C1 (ru) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
JP7514598B2 (ja) * 2018-12-20 2024-07-11 小林製薬株式会社 皮膚外用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32084B1 (en) 1967-06-07 1973-04-04 Wyeth John & Brother Ltd Thiazole derivatives
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
US4659728A (en) 1985-02-25 1987-04-21 American Home Products Corporation Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid
EP0270316A3 (en) * 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
WO1995011017A1 (en) 1993-10-20 1995-04-27 The Boots Company Plc Ibuprofen and flurbiprofen as anti-pruritic agents
JPH07316075A (ja) 1994-05-26 1995-12-05 Pola Chem Ind Inc 皮膚外用剤
GB9606429D0 (en) 1996-03-27 1996-06-05 Boots Co Plc Pharmaceutical compositions
BR9710448A (pt) * 1996-05-20 1999-08-17 Searle & Co Formula-{es farmac-uticas de sal de pot ssio sÄdioe tris oxaprozina
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050232957A1 (en) 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin

Also Published As

Publication number Publication date
EA200702027A1 (ru) 2008-02-28
WO2006102898A3 (en) 2006-12-28
EP1707199A1 (en) 2006-10-04
MX2007012050A (es) 2008-03-11
WO2006102900A1 (en) 2006-10-05
BRPI0609535A2 (pt) 2010-04-13
IL186021A0 (en) 2008-02-09
WO2006102899A2 (en) 2006-10-05
CA2605121A1 (en) 2006-10-05
NO20075227L (no) 2007-12-09
IL186022A0 (en) 2008-02-09
WO2006102899A3 (en) 2006-12-28
JP2008534526A (ja) 2008-08-28
EA200702026A1 (ru) 2008-04-28
KR20080005526A (ko) 2008-01-14
EP1707200A1 (en) 2006-10-04
MX2007012051A (es) 2008-02-22
EP1707201A1 (en) 2006-10-04
WO2006102898A2 (en) 2006-10-05
ECSP077843A (es) 2008-02-20
IL186020A0 (en) 2008-01-20
NO20075218L (no) 2007-12-27
JP2008534528A (ja) 2008-08-28
AU2006228869A1 (en) 2006-10-05
CA2603300A1 (en) 2006-10-05
JP2008534527A (ja) 2008-08-28
EA200702023A1 (ru) 2008-04-28
CA2603297A1 (en) 2006-10-05
KR20080005525A (ko) 2008-01-14
MX2007012052A (es) 2008-02-22
AU2006228870A1 (en) 2006-10-05
KR20080011280A (ko) 2008-02-01
NO20075199L (no) 2008-01-02
ECSP077846A (es) 2008-02-20
BRPI0609653A2 (pt) 2010-04-20
AU2006228871A1 (en) 2006-10-05
ECSP077845A (es) 2008-02-20

Similar Documents

Publication Publication Date Title
EA200801716A1 (ru) Тиазольные соединения и их применение
WO2009011880A3 (en) Heterocyclic modulators of pkb
UY30816A1 (es) Compuestos activos en proteina quinasa, composicionesconteniéndolos y plicaciones
WO2009011871A3 (en) Thiadiazole modulators of pkb
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
CL2007001504A1 (es) Compuestos derivados de purina o pirrolopirimidina; y uso para regular, modular o inhibir la actividad de la proteina cinasa en enfermedades tales como cancer, rechazo de transplantes y enfermedades autoinmunes.
WO2006131835A3 (en) Heterocyclic triazines as hypoxic selective protein kinase inhibitors
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
CL2007002836A1 (es) Compuestos derivados de 1,3,5-triazina o pirimidina, inhibidores de quinasa; composicion farmaceutica; y uso para tratar una enfermedad mediada por quinasa, tal como cancer.
WO2009073546A3 (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
BR112013032720A2 (pt) "derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
WO2008080015A3 (en) Compounds and methods for kinase modulation, and indications therefor
BRPI0923231B8 (pt) anticorpo anti-cmet
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
EA201001456A1 (ru) Новые гетероциклические соединения и их применение
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
BRPI0607240A2 (pt) derivados de maleimida, composições farmacêuticas e métodos para tratamento de cáncer
BRPI0701684A (pt) composição cosmética ou farmacêutica, processo de tratamento cosmético, uso de um composto e composto
ATE528302T1 (de) 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
EA201000515A1 (ru) Активаторы глюкокиназы

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]